Amador Bioscience is a global translational and clinical CRO, providing global-standard (GLP/GCP) laboratory, clinical research, strategy consulting, and regulatory filing services to leading pharmaceutical companies in both China and the U.S. The laboratory services focus on bioanalysis, biomarkers and immunogenicity assessment. The clinical research unit specializes in innovative clinical development strategy, protocol design, study initiation and monitoring of clinical studies in China and the U.S. In addition to the R&D strategy and regulatory pathway, the consulting services perform global-standard data analysis and generate submission-ready study reports.
Amador team, 25% with doctoral degree (PhD, MD, PharmD) and 40% with master degree, have extensive experience and in-depth expertise in clinical pharmacology, biostatistics, programing, bioanalysis, biomarkers, clinical medicine, clinical trial management, data management, project management, quality assurance, and regulatory submission.
Amador is committed to supporting innovative drug development from early drug discovery to clinical development and regulatory filling. We are providing global-standard, integrated services for dozens of companies in China & U.S. (more than 50% from U.S.), including a number of successful IND/BLA filings in both China and U.S. Amador Bioscience operates in the U.S. (San Francisco Bay Area, Virginia, etc.) and China (Hangzhou and Beijing).